How Are Institutional Investors Positioning Themselves in Sarepta Therapeutics (NASDAQ:SRPT)?

3 min read | February 19, 2025 12:00 AM PST | By Team Kalkine Media

How Are Institutional Investors Positioning Themselves in Sarepta Therapeutics (NASDAQ:SRPT)? — Image source: shutterstock

Institutional Investment Surge

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has seen a considerable increase in institutional investments, highlighting a growing focus on the biotechnology firm. Allspring Global Investments Holdings LLC made a significant move by increasing its stake by 16,717.7% in the fourth quarter. The company now owns 85,434 shares, accounting for 0.09% of Sarepta’s total stock, with an estimated value of $10.6 million.

This trend extends beyond a single entity. Blue Trust Inc. also expanded its holdings by 896.5% in the third quarter, bringing its total ownership to 568 shares worth approximately $71,000. Meanwhile, Bank Pictet & Cie Europe AG and Mirae Asset Global Investments Co. Ltd. saw their stakes rise by 27.7% and 112.7%, respectively. These movements suggest heightened interest in Sarepta’s potential within the biotechnology sector.

Stock Performance and Market Positioning

Sarepta’s stock opened at $105.35 recently, with a market capitalization of $10.06 billion. The company maintains a steady financial standing, supported by its innovative drug pipeline and strategic research initiatives.

Following recent corporate transactions, approximately 7.70% of the company’s stock remains under company ownership. This suggests a strong internal commitment to Sarepta’s long-term objectives, reinforcing its focus on advancing treatments for rare diseases.

Market Ratings and Financial Perspectives

Recent financial reports have attracted attention from industry experts, leading to adjustments in stock evaluations. Some market observers have maintained a favorable stance on Sarepta’s trajectory. For example, Needham & Company LLC reiterated its expectations, setting a stock price objective of $202.

However, others have taken a more reserved approach. Piper Sandler adjusted its target price slightly downward to $182, emphasizing a range of perspectives on the stock’s movement. Despite these variations, the company continues to remain a focal point in the biotechnology sector.

Sarepta’s Core Business and Industry Role

Sarepta Therapeutics specializes in developing treatments for rare genetic disorders, with a focus on RNA-targeted therapies and gene therapy solutions. The company is primarily recognized for its contributions to treating Duchenne muscular dystrophy (DMD). Among its flagship products are EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, all designed to address specific genetic mutations linked to DMD.

Beyond its existing portfolio, Sarepta continues to invest in research and development, expanding its therapeutic capabilities in genetic medicine. Its role in advancing RNA-based drug development places it among the key players in the biopharmaceutical sector.

As institutional investors increase their involvement, Sarepta Therapeutics remains a key entity in rare disease treatment advancements, with ongoing developments shaping its market positioning.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.